Company Overview

Wellbeing Digital Sciences Inc. (OTC: KONEF) is a Canadian health and wellness technology company focused on mental health, behavioral health, and psychedelic medicine-related care delivery. The company has operated at the intersection of digital therapeutics, clinical services, and data-driven healthcare, with activities spanning telehealth platforms, mental health clinics, and technology-enabled wellness solutions. Its business model has historically centered on integrating clinical treatment programs with digital patient engagement and monitoring tools designed to support mental health outcomes.

The company’s principal revenue drivers have included clinical mental health services, digital healthcare technologies, and investments in healthcare-related subsidiaries and operating platforms. Wellbeing Digital Sciences pursued a strategy aimed at combining healthcare delivery with emerging psychedelic-assisted therapies and evidence-based behavioral health programs. Public disclosures and market reporting indicate the company evolved through acquisitions and investments in mental health clinics, telehealth assets, and wellness technology businesses following its formation and public market listing in Canada and the United States. Some operational and financial details have varied across reporting periods, and certain business initiatives appear to have shifted as the company restructured portions of its portfolio.

Business Operations

Wellbeing Digital Sciences has historically operated through a collection of healthcare and wellness-related subsidiaries and investments. Its operations included clinical treatment services, digital health infrastructure, and behavioral health technologies. Key operating activities included outpatient mental health treatment, telemedicine-enabled care, patient monitoring platforms, and healthcare analytics initiatives. The company also explored applications tied to psychedelic-assisted treatment protocols and integrated behavioral care programs. Revenue generation primarily came from healthcare service delivery, clinic operations, and technology-related healthcare offerings.

The company maintained exposure to both Canadian and U.S. healthcare markets through subsidiaries, partnerships, and operating entities. Public filings and investor materials have referenced interests in businesses such as KGK Science, a clinical research organization, and healthcare technology and treatment platforms associated with mental wellness and patient engagement. Certain subsidiaries and investments underwent strategic review or restructuring activity as the company adjusted capital allocation priorities. Data regarding the current operational scale of some business units is inconclusive based on available public sources.

Strategic Position & Investments

Wellbeing Digital Sciences positioned itself within the broader digital mental health and psychedelic medicine ecosystem by pursuing acquisitions, strategic investments, and technology integration initiatives. The company emphasized combining clinical care delivery with digital therapeutic support systems, seeking differentiation through integrated healthcare infrastructure rather than purely pharmaceutical development. Strategic initiatives included expansion into telehealth-enabled behavioral care and participation in emerging psychedelic-assisted treatment markets where regulatory frameworks permitted research or clinical application.

The company has previously invested in or acquired healthcare-related businesses intended to broaden its clinical and technology capabilities. These included interests connected to research services, mental health clinics, and digital patient engagement tools. Public disclosures also reflected efforts to establish scalable healthcare delivery systems supported by data analytics and remote care technologies. While management communicated growth ambitions tied to mental health demand and evolving treatment models, the pace and scope of expansion have been affected by broader capital market conditions impacting healthcare and psychedelic-sector companies.

Geographic Footprint

Wellbeing Digital Sciences is headquartered in Canada and has maintained operational exposure across both North America and selected international healthcare-related activities through subsidiaries and partnerships. Its core market presence has historically been concentrated in Canada and the United States, particularly in mental health services, digital healthcare, and clinical research operations.

The company’s investments and business interests reflected participation in healthcare sectors with international relevance, including digital therapeutics, clinical research, and behavioral health technologies. Certain subsidiaries and affiliated operations supported cross-border healthcare activities, especially in research and telehealth-related services. Available public information indicates that the company’s principal operational influence remained strongest within North American healthcare markets.

Leadership & Governance

Wellbeing Digital Sciences has been led by executives with backgrounds in healthcare, finance, technology, and capital markets. The company’s governance strategy emphasized building an integrated healthcare platform focused on mental wellness, technology-enabled care delivery, and emerging treatment modalities. Management communications historically highlighted patient-centered healthcare innovation, clinical integration, and strategic acquisition-led growth.

Key executives and leadership figures publicly associated with the company have included:

• Najla Guthrie – Chief Executive Officer
• Adam O’Brien – Chairman
• Jeff Stevens – Chief Financial Officer
• Brian Cass – Executive associated with subsidiary operations and clinical research activities

Leadership composition and executive responsibilities have changed over time as part of corporate restructuring and strategic realignment efforts. Certain executive appointments and operational roles may differ across reporting periods based on available public disclosures.